NRPR 09/18/07 : NPRI Collaborates with Baylor University
September 18, 2007 - 4:07 PM EDT
O2P™ Technology to Support Clinical Research Study with the Institute of Metabolic Disease
Nutri Pharmaceuticals Research, Inc. (Pink Sheets: NRPR) announced today that it has been selected to collaborate on the development of a dry formulation for Triheptanoin by Dr. Charles Roe, Medical Director of the Institute of Metabolic Disease at Baylor University Medical Center, Dallas. Triheptanoin is a unique medium-odd chain triglyceride that has provided significant benefit to many patients with inherited biochemical disorders. Clinical features of these disorders can include muscle weakness, pain and breakdown of muscle tissue (rhabdomyolysis), and cardiomyopathy (disease of the heart muscle) all resulting from the lack of proper energy production within the cells.
Working closely with the Institute of Metabolic Disease, NRPR will utilize its patent-pending O2P™ process to partner with Dr. Roe’s investigative staff to produce an exact duplication of this compound’s beneficial metabolic effects, only in a dry powder form. "NRPR is pleased to be helping the Institute in the development of an alternative delivery form for its formulation. In a relatively short period of time, we have been able to produce a dry form with the same metabolic characteristics as the original liquid formula,” stated Godfrey Yew, president and CEO of NRPR.
According to lead researcher, Dr. Charles Roe, Medical and Clinical Investigation Director of the Institute of Metabolic Disease, “We have found that the O2P process is perfectly suited for extending our existing treatment for the restoration of energy production and improved cardiac and skeletal muscle function. The lack of heat and a controlled atmosphere eliminate oxidative effects while preserving the efficacy of triheptanoin in a water soluble dry powder form.” According to Dr. Roe, the powder form will be used for Phase II clinical studies.
About the Institute of Metabolic Disease:
The Institute of Metabolic Disease (IMD) was established to diagnose and study inherited metabolic disease. Since its creation, the IMD has developed outstanding clinical, research and educational programs and is now recognized as a world-renowned research institute in metabolic disease specializing in the development of new and more effective treatment protocols for patients with inherited and acquired metabolic disorders.
About NRPR:
Nutri Pharmaceuticals Research Inc. (www.o2pus.com) provides a wide range of powdered oils for functional food, food supplement; pharmaceutical; cosmetic; pet food and animal feed applications.
The company is one of a select few to be awarded the prestigious Nutrition Business Journal "Product Merit Award" for its patent-pending O2P™ Powderization process. At the heart of its oil powders is the O2P™ Oil-to-Powder technology. This patent-pending process converts most edible oils, gels or pastes into a free-flowing powder without affecting the isomeric structure, fatty acid profile, color, taste or aroma of the base oil. O2P™ does not rely on traditional techniques that utilize extremes in heat or cold, micro-encapsulation or nano technology. This facilitates food marketing and supplement producers' ability to create functional foods and nutraceuticals by adding anti-oxidants, specific EFAs, or other fatty acids such as EPA, GLA, DHA, and CLA to assist in maintaining specific health issues.
The company currently offers more than 50 shelf-stable powders. The company can also apply O2P™ technology to a third-party's oil, paste or gel through an arrangement called tolling. Based in Las Vegas, the company has representative sales offices near Chicago, Amsterdam, Guatemala City and Bangkok.
Nutri Pharmaceuticals Research Inc. shares are currently traded in the United States on the "Pinksheets" under the symbol NRPR.PK.
Princeton Research, Inc.
Mike King, 702-650-3000
mike@princetonresearch.com
or
Nutri Pharmaceuticals Research, Inc.
Godfrey Yew, 702-309-8627, ext. 201
godfrey@o2pus.com
Fabio Sunago, 702-467-2345
fabio@o2pus.com
Source: Business Wire (September 18, 2007 - 4:07 PM EDT)
News by QuoteMedia
www.quotemedia.com
DIVERSIFICATION IS RULE #1 -- YOU ALONE ARE RESPONSIBLE FOR YOUR INVESTMENT DECISIONS -- ALWAYS CONDUCT YOUR OWN DUE DILIGENCE -- NEVER INVEST MORE THAN YOU CAN AFFORD TO LOSE -- HOPE IS NOT AN INVESTMENT STRATEGY -- PATIENCE !!!
AI
